Emmanuel S. Antonarakis, MBBCh, assistant professor, Johns Hopkins Medicine, discusses the results of a trial that examined AR-V7 and resistance to enzalutamide and abiraterone in patients with prostate cancer.
Emmanuel S. Antonarakis, MBBCh, assistant professor, Johns Hopkins Medicine, discusses the results of a trial that examined AR-V7 and resistance to enzalutamide and abiraterone in patients with prostate cancer.
Clinical Pearls
The study showed that about 39% (12 of 31) of patients in the enzalutamide arm had AR-V7 detected in their circulating tumor cells.
Every patient taking enzalutamide that had AR-V7 did not obtain a PSA response to enzalutamide.
In the abiraterone arm, 19% (6 of 31) were found to have AR-V7.
Similarly, all of these patients demonstrated resistance to abiraterone. ​
